Harro Höfliger is a shareholder in the start-up DiHeSys (Digital Health Systems GmbH). Together, the companies want to help shape the future of personalized medicine.
Harro Höfliger Verpackungsmaschinen GmbH is investing in the healthcare provider DiHeSys. In May of this year, the two companies announced that they would enter into a strategic alliance to develop medication printing for personalized therapy. The focus of this partnership is to enable the production of patient-specific thin films and tablets. The investment will also strengthen the partnership financially.
DiHeSys' vision is to provide a complete system for personalized 2D and 3D printing of medicines. In addition to the printers themselves, this also includes the development of active ingredient-containing inks and filaments, as well as software and services related to the digital printing of personalized medicine. In addition, the company also has aspects such as the provision of cartridges and data management in mind. Harro Höfliger, as a technological partner, offers support for the construction of the GMP-compliant printers.
"For us, joining DiHeSys is a logical step because we are convinced of the potential of the DiHeSys concept," explains Thomas Weller, CEO of Harro Höfliger. "We are also reacting to the great response from the market - initial studies with the pharmaceutical printers are already underway. We also see the investment as very sustainable against the backdrop of the corona pandemic, which has led to a digitalization push in the healthcare sector. DiHeSys is very active in the field of data management, among other things, and therefore has the best prerequisites to establish itself as a technology leader in the field of personalized medicine."
Markus Dachtler, CEO at DiHeSys, also emphasizes that the partnership lays an important foundation for the future: "Among other things, we have the pharmaceutical know-how necessary for formulation development. At the same time, Harro Höfliger supports us with all technological challenges and thus has our backs. Together, we have the best prerequisites to actively shape the future of personalized medicine."
Comments